A promising drug candidate can show strong biological activity and still encounter a serious development delay. An unresolved impurity peak, an unstable assay or a method that cannot reproduce results on another instrument may call months of work into question. The analytical methods drug development teams select determine whether scientists can confidently evaluate identity, purity, potency, stability and product performance. These methods are not simply final quality-control tests. They generate the evidence used to make decisions throughout discovery, formulation, scale-up, regulatory submission and commercialisation. Quick summary: Analytical methods in drug development identify, quantify, characterise and monitor drug substances, products, impurities and degradation products. Reliable methods support compound selection, process optimisation, formulation development, stability studies, regulatory submissions, method transfer and quality control by producing accurate, traceable and fit-for-purpose data. An analytical method is a defined scientific procedure used to identify, measure or characterise a chemical, physical or biological attribute of a sample. The procedure may specify the instrument, sample preparation, reference materials, reagents, operating conditions, calculations, system-suitability criteria and reporting requirements. In pharmaceutical development, analytical methods help answer essential questions: The appropriate technology depends on the analytical target, sample matrix, required sensitivity and development phase. High-performance liquid chromatography, or HPLC, separates components in a sample and is commonly used for API assay, related-substance testing, dissolution testing and impurity profiling. Ultra-performance liquid chromatography, or UPLC, applies similar separation principles while supporting faster analysis and high chromatographic resolution under suitable conditions. Liquid chromatography–tandem mass spectrometry, or LC-MS/MS, combines chromatographic separation with sensitive mass detection. It can support impurity identification, metabolite analysis, biomarker measurement and quantitative bioanalysis. Gas chromatography and GC-MS are suited to volatile and semi-volatile compounds, including residual solvents, process contaminants and volatile degradation products. Nuclear magnetic resonance spectroscopy, or NMR, provides detailed structural information that can confirm molecular identity and help characterise unknown compounds or impurities. Fourier-transform infrared spectroscopy and UV-Visible spectroscopy support identification, functional-group analysis, concentration measurements and complementary structural assessment. ICP-MS, ICP-AES and ICP-OES can measure elemental impurities and trace metals at low concentrations. Other tools such as XRPD, DSC, dynamic light scattering and particle-size analysis may be used to study polymorphism, thermal behaviour, particle distribution and formulation characteristics. No single instrument answers every development question. A scientifically sound analytical programme selects complementary or orthogonal techniques based on the intended purpose of the method. Analytical testing supports almost every major decision in a pharmaceutical programme. The method should evolve as the project moves from early research into clinical development and, where applicable, commercial quality control. Early analytical methods confirm the identity and purity of newly synthesised compounds. They also help medicinal chemists distinguish genuine biological activity from results affected by contaminants, incorrect concentration or chemical instability. Fast, fit-for-purpose methods can support: At this stage, the method may not require full regulatory validation. It must still generate sufficiently reliable data for the decision being made. As a candidate progresses, analytical methods support toxicology material characterisation, dose preparation, bioanalytical measurements and stability assessment. The required sensitivity may also increase. LC-MS/MS, for example, can quantify a drug or metabolite in complex biological matrices when conventional chromatographic detection does not provide adequate selectivity or sensitivity. Changing a synthetic route, raw-material supplier, reaction condition or purification process may alter the impurity profile. Analytical methods allow process chemists to determine whether those changes improve yield without compromising material quality. In-process testing can reveal: Early detection of these issues helps prevent unsuitable processes from advancing into more expensive scale-up work. A method that performs well for a neat API may not work after the compound is combined with excipients. Matrix interference, extraction recovery, solubility and degradation behaviour can all affect the reported result. Formulation-supporting methods may assess: Reliable analytical data allows formulators to compare prototypes and select compositions that protect potency, stability and performance. A stability-indicating method can measure the active ingredient without interference from impurities, excipients or degradation products. It must distinguish meaningful chemical changes from normal analytical variation. Forced degradation studies expose a drug substance or product to controlled stress conditions such as heat, oxidation, light and acidic or alkaline environments. These studies help reveal likely degradation pathways and determine whether a proposed method can detect relevant changes. Methods used to support release, stability and specification testing require a defined level of validation. The supporting package should demonstrate that the procedure is suitable for its intended purpose and produces dependable results within its reportable range. Depending on the method, validation may evaluate: Incomplete validation or weak documentation can lead to additional experiments, regulatory questions and method-transfer difficulties. ARSI Canada Inc. provides customized analytical method development, validation, impurity profiling, structure elucidation, forced degradation, pharmaceutical testing and technical-transfer support. Its Mississauga-based scientific team applies chromatography, mass spectrometry, spectroscopy and physical characterisation techniques according to the molecule, matrix, development phase and intended use of the data. ARSI Canada defines the analytical objective before selecting an instrument or experimental design. A rapid purity method for synthetic route screening has different requirements from a stability-indicating method intended for a regulatory submission. The scope can therefore be adjusted according to: This phase-appropriate strategy prevents early projects from carrying unnecessary analytical complexity while creating a path toward stronger validation as the programme matures. ICH Q14 describes science and risk-based approaches to analytical procedure development and lifecycle management. ICH Q2(R2) addresses the selection and evaluation of validation studies used to show that a procedure is fit for its intended purpose. For Canadian pharmaceutical projects, Health Canada guidance also influences qualification, validation, GMP documentation and data-integrity expectations. When a project involves food, nutraceutical or feed-related matrices, applicable CFIA testing requirements may also need to be considered separately from pharmaceutical drug requirements. The applicable framework depends on the product, development phase, intended market and regulatory use of the results. Analytical work becomes more efficient when it is coordinated with synthesis, impurity isolation, process development, formulation or scale-up activities. ARSI Canada can connect analytical findings with related work such as: This integrated model reduces handoffs between unrelated providers and allows analytical findings to inform the next experimental decision. Although every project requires a customised protocol, a structured analytical development programme commonly follows these steps. The project begins by identifying what the procedure must measure and why the result is needed. The analytical target may include API assay, identity, purity, potency, residual solvents, trace metals, dissolution, degradation products, process impurities or a compound in a biological matrix. Acceptance criteria, sensitivity needs and intended regulatory use should be considered from the beginning. Scientists evaluate available information about the analyte and sample, including: This assessment guides sample preparation, detection technology and experimental conditions. The technology should match the scientific question rather than forcing the sample into a familiar platform. HPLC or UPLC may be selected for assay and impurity separation. GC may be more appropriate for volatile compounds. LC MS/MS can provide high sensitivity and molecular information, while NMR may be needed for structural confirmation. Orthogonal techniques may be combined when one procedure cannot provide adequate discrimination. Method development evaluates the variables that influence performance. For an HPLC procedure, these may include: Development should establish conditions that produce adequate resolution, appropriate sensitivity, consistent peak shape and practical run times. Potential interferences should be assessed using blank matrices, excipients, known impurities, spiked samples, process samples or stressed materials. Forced degradation may be used to generate degradation products and demonstrate that the method can measure the analyte in their presence. Robustness examines whether normal, deliberate variations in method parameters affect performance. These variations may include small changes in flow rate, pH, temperature, mobile-phase composition, extraction time or instrument conditions. A robust method should tolerate realistic operating variation while continuing to meet predefined performance criteria. A validation protocol defines the characteristics to be tested, experimental design and acceptance criteria. The extent of validation should reflect the method’s purpose, development phase and associated risk. The study results are then summarised in a validation report with supporting data, calculations, deviations and conclusions. A transfer-ready method requires more than instrument settings. It should include detailed sample preparation, reagent instructions, calculations, integration expectations, system-suitability requirements, troubleshooting guidance and representative chromatograms or spectra. Comparative testing, partial revalidation or co-validation may be appropriate when a method moves between laboratories. Methods may require reassessment after changes to: A documented risk assessment determines whether the change requires verification, partial revalidation or full revalidation. A method can produce acceptable results during development and still fail during transfer or routine use. Common causes include inadequate robustness studies, poorly controlled sample preparation, undocumented integration decisions or unrealistic system-suitability criteria. These failures consume reference standards, analyst time, instruments and valuable project material. Designing for routine use and transfer from the beginning can reduce repeat experiments and avoid late-stage redevelopment. Pharmaceutical developers can use ARSI Canada for API and drug-product method development, impurity analysis, stability-indicating procedures, forced degradation, validation and method-transfer support. Smaller biotechnology organisations may not have every required analytical platform or internal specialist. Flexible CRO support provides access to doctorate-level scientific expertise without the fixed cost of building a complete in-house laboratory. Medical device programmes may require chemical characterisation, residue analysis, trace-element testing, cleaning studies or the investigation of substances associated with device materials and manufacturing processes. Universities and research centres can access specialised instrumentation and interpretation for compound identification, structural elucidation, purity confirmation and collaborative development projects. Projects involving unknown degradation products, genotoxic impurities, nitrosamine risks, residual solvents or elemental impurities may require complementary separation, mass-spectrometric and spectroscopic techniques. ARSI Canada combines an agile specialised-CRO model with more than 50 years of cumulative team experience in pharmaceutical research, analytical support and drug development. Clients benefit from: The objective is not to generate data for its own sake. It is to produce scientifically meaningful results that help clients make faster decisions, reduce avoidable rework, control development risks and prepare stronger technical packages. Trustworthy analytical results require a traceable connection between the sample, procedure, instrument output, calculation, review and reported conclusion. Depending on the project scope, the analytical package may include: When data supports GMP-regulated activities, records should follow appropriate data-governance, documentation and lifecycle controls. Clear traceability allows clients, quality teams, receiving laboratories and regulators to understand how a result was generated and why it is scientifically defensible. Analytical methods identify and quantify drug substances, products, impurities, degradation products and other quality attributes. They support compound selection, synthesis, formulation, process development, stability testing, specification setting, regulatory submissions, batch release and lifecycle management by generating reliable evidence about identity, purity, potency and performance. Analytical method development should begin during early discovery or candidate development, as soon as reliable identity, purity or concentration data is needed. Early methods can remain fit for purpose and phase appropriate. They should then be strengthened, optimised and validated as the programme approaches clinical, regulatory or routine quality-control use. Method development creates and optimises the procedure, including sample preparation, instrument conditions, detection and system-suitability requirements. Method validation generates documented evidence that the completed procedure performs as intended. Validation may examine specificity, accuracy, precision, response, range, detection capability, quantitation capability and robustness. Common technologies include HPLC, UPLC, GC, LC-MS/MS, GC-MS, NMR, FTIR, UV-Vis, ICP-MS and ICP-OES. Physical techniques such as XRPD, DSC, particle-size analysis and dynamic light scattering may also be used. Selection depends on the analy, FTIR, UV-Vis, ICP-MS and ICPte, matrix, required sensitivity and intended result. Yes. A validated analytical method can be transferred through comparative testing, co-validation, partial revalidation or another scientifically justified approach. Successful transfer requires detailed procedures, trained analysts, suitable instruments, predefined acceptance criteria and representative samples. Transfer planning should be incorporated during development rather than treated as an afterthought. The timeline depends on the molecule, matrix, required sensitivity, impurity complexity, reference-standard availability, regulatory purpose and validation scope. A straightforward assay may progress quickly, while a stability-indicating impurity method involving unknown degradation products may require additional separation, isolation and structural-characterisation work. Reliable analytical methods help development teams distinguish promising results from analytical uncertainty. They also provide the foundation for formulation decisions, impurity control, stability programmes, regulatory documentation and reproducible quality testing. ARSI Canada Inc. supports pharmaceutical, biotechnology, medical device and academic organisations across Canada and North America from its specialised CRO facility in Mississauga, Ontario. Contact ARSI Canada to discuss your molecule, analytical challenge, development stage and required timeline.What Are Analytical Methods in Drug Development?
Common analytical technologies
Why Analytical Methods Drug Development Teams Use Matter at Every Stage
1. Drug discovery and lead optimisation
2. Preclinical development
3. Process development and scale-up
4. Formulation development
5. Stability testing and shelf-life development
6. Regulatory submission and quality control
How ARSI Canada Approaches Analytical Methods in Drug Development
What does ARSI Canada offer for analytical methods drug development projects?
Phase-appropriate method development
Alignment with recognised scientific principles
Integrated analytical and development support
Our Analytical Methods Drug Development Process
1. Define the analytical target
2. Review the molecule, matrix and known risks
3. Select the analytical platform
4. Develop and optimise the method
5. Challenge selectivity and stability indication
6. Evaluate robustness
7. Validate according to intended use
8. Document and transfer the procedure
9. Manage the method through its lifecycle
The hidden cost of a method that works only on one instrument
Who Can Benefit from ARSI Canada’s Analytical Method Services?
Pharmaceutical companies
Biotechnology startups
Medical device companies
Academic research institutions
Organisations managing complex impurities
Why Choose ARSI Canada for Analytical Methods in Drug Development?
Documentation, Data Integrity and QC Traceability
Frequently Asked Questions
What are analytical methods used in drug development?
When should analytical method development begin?
What is the difference between method development and method validation?
Which analytical techniques are commonly used in pharmaceutical development?
Can an analytical method be transferred to another laboratory?
How long does analytical method development take?
Build a Stronger Analytical Foundation with ARSI Canada
